AEON vs. TPST, DTIL, CLNN, MDCX, ELEV, ANVS, CASI, ATHE, SRZN, and INKT
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Tempest Therapeutics (TPST), Precision BioSciences (DTIL), Clene (CLNN), Medicus Pharma (MDCX), Elevation Oncology (ELEV), Annovis Bio (ANVS), CASI Pharmaceuticals (CASI), Alterity Therapeutics (ATHE), Surrozen (SRZN), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.
AEON Biopharma vs.
Tempest Therapeutics (NASDAQ:TPST) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 7.0% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Tempest Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for AEON Biopharma. Tempest Therapeutics' average media sentiment score of 0.49 beat AEON Biopharma's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.
Tempest Therapeutics has a beta of -1.69, meaning that its stock price is 269% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
Tempest Therapeutics presently has a consensus target price of $21.67, suggesting a potential upside of 2,418.21%. AEON Biopharma has a consensus target price of $5.00, suggesting a potential upside of 4,056.28%. Given AEON Biopharma's higher possible upside, analysts clearly believe AEON Biopharma is more favorable than Tempest Therapeutics.
AEON Biopharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity.
Tempest Therapeutics received 92 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote.
Tempest Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
AEON Biopharma beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:AEON) was last updated on 2/22/2025 by MarketBeat.com Staff
